Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicenna Therapeutics Corp (OP:MDNAF)

1.080 +0.039 (+3.75%)
Streaming Delayed Price Updated: 11:17 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medicenna Therapeutics Corp

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna Therapeutics Announces Participation in Upcoming Conferences
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna Announces Results of Annual Meeting of Shareholders
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation... 
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
Via Stocktwits
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
From Medicenna Therapeutics Corp.
Via GlobeNewswire
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
From OTC Markets
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.